Evidence map›Paper›PMID 26416867›Full record

ArticleAntimicrobial agents and chemotherapy2015

Fitness Cost of Rifampin Resistance in Neisseria meningitidis: In Vitro Study of Mechanisms Associated with rpoB H553Y Mutation.

Roberta Colicchio, Chiara Pagliuca, Gabiria Pastore, Annunziata Gaetana Cicatiello, Caterina Pagliarulo, Adelfia Talà, Elena Scaglione, Josè Camilla Sammartino, Cecilia Bucci, Pietro Alifano and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Frontiers in cellular and infection microbiology · 2024
    Article
  3. Antimicrobial efficacy ofFrontiers in microbiology · 2024
    Article
  4. Article
  5. Environmental Dependence of Competitive Fitness in Rifampin-ResistantApplied and environmental microbiology · 2022
    Article
  6. Microbiology (Reading, England) · 2020
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Roberta ColicchioDepartment of Molecular Medicine and Medical Biotechnology, Federico II University Medical School, Naples, Italy SDN-Foundation, Naples, Italy.
Chiara PagliucaDepartment of Molecular Medicine and Medical Biotechnology, Federico II University Medical School, Naples, Italy Ceinge Advanced Biotechnologies, Naples, Italy.
Gabiria PastoreDepartment of Sciences and Technologies, University of Sannio, Benevento, Italy.
Annunziata Gaetana CicatielloDepartment of Molecular Medicine and Medical Biotechnology, Federico II University Medical School, Naples, Italy.
Caterina PagliaruloDepartment of Sciences and Technologies, University of Sannio, Benevento, Italy.
Adelfia TalàDepartment of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy.
Elena ScaglioneDepartment of Molecular Medicine and Medical Biotechnology, Federico II University Medical School, Naples, Italy.
Josè Camilla SammartinoDepartment of Molecular Medicine and Medical Biotechnology, Federico II University Medical School, Naples, Italy.
Cecilia BucciDepartment of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy.
Pietro AlifanoDepartment of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy pietro.alifano@unisalento.it psalvato@unina.it.
Paola SalvatoreDepartment of Molecular Medicine and Medical Biotechnology, Federico II University Medical School, Naples, Italy Ceinge Advanced Biotechnologies, Naples, Italy pietro.alifano@unisalento.it psalvato@unina.it.
Federico II University Hospital · ITUniversity of Salento · ITUniversity of Sannio · ITCeinge Biotecnologie Avanzate (Italy) · ITSDN Istituto di Ricerca Diagnostica e Nucleare · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rifampin chemoprophylaxis against Neisseria meningitidis infections led to the onset of rifampin resistance in clinical isolates harboring point mutations in the rpoB gene, coding for the RNA polymerase β chain. These resistant strains are rare in medical practice, suggesting their decreased fitness in the human host. In this study, we isolated rifampin-resistant rpoB mutants from hypervirulent serogroup C strain 93/4286 and analyzed their different properties, including the ability to grow/survive in different culture media and in differentiated THP-1 human monocytes and to compete with the wild-type strain in vitro. Our results demonstrate that different rpoB mutations (H553Y, H553R, and S549F) may have different effects, ranging from low- to high-cost effects, on bacterial fitness in vitro. Moreover, we found that the S549F mutation confers temperature sensitivity, possibly explaining why it is observed very rarely in clinical isolates. Comparative high-throughput RNA sequencing analysis of bacteria grown in chemically defined medium demonstrated that the low-cost H553Y substitution resulted in global transcriptional changes that functionally mimic the stringent response. Interestingly, many virulence-associated genes, including those coding for meningococcal type IV pili, porin A, adhesins/invasins, IgA protease, two-partner secretion system HrpA/HrpB, enzymes involved in resistance to oxidative injury, lipooligosaccharide sialylation, and capsular polysaccharide biosynthesis, were downregulated in the H553Y mutant compared to their level of expression in the wild-type strain. These data might account for the reduced capacity of this mutant to grow/survive in differentiated THP-1 cells and explain the rarity of H553Y mutants among clinical isolates.

Indexed as

Gene Expression Regulation, BacterialGenetic FitnessAdhesins, BacterialAmino Acid SubstitutionAnti-Bacterial AgentsBacterial ProteinsCell LineCulture MediaDNA-Directed RNA PolymerasesDrug Resistance, Multiple, BacterialHigh-Throughput Nucleotide SequencingHumansMonocytesMutationNeisseria meningitidisPorinsAdhesins, BacterialAnti-Bacterial AgentsBacterial ProteinsCulture MediaDNA-Directed RNA PolymerasesHrpA protein, Neisseria meningitidisIgA-specific serine endopeptidaseporin protein, NeisseriaPorinsRifampinSerine EndopeptidasesVirulence Factors

Identifiers

PMID26416867
PMCPMC4649176
OpenAlexW2248582126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.